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Abstract
Purpose Genetic predisposition to male breast cancer
(MBC) is not well understood. The aim of this study was to
better define the predisposition genes contributing to MBC
and the utility of germline multi-gene panel testing
(MGPT) for explaining the etiology of MBCs.
Methods Clinical histories and molecular results were
retrospectively reviewed for 715 MBC patients who
underwent MGPT from March 2012 to June 2016.
Results The detection rate of MGPT was 18.1% for patients
tested for variants in 16 breast cancer susceptibility genes
andwith no priorBRCA1/2 testing.BRCA2 andCHEK2were
themost frequentlymutated genes (11.0 and 4.1% of patients
with no prior BRCA1/2 testing, respectively). Pathogenic
variants in BRCA2 [odds ratio (OR) = 13.9; p = 1.92 9
10-16], CHEK2 (OR = 3.7; p = 6.24 9 10-24), and
PALB2 (OR = 6.6, p = 0.01) were associated with signifi-
cantly increased risks of MBC. The average age at diagnosis
of MBCwas similar for patients with (64 years) and without
(62 years) pathogenic variants. CHEK2 1100delC carriers
had a significantly lower average age of diagnosis (n = 7;
54 years) than all otherswith pathogenic variants (p = 0.03).
No significant differences were observed between history of
additional primary cancers (non-breast) and family history of
male breast cancer for patients with and without pathogenic
variants. However, patients with pathogenic variants in
BRCA2 were more likely to have a history of multiple pri-
mary breast cancers.
Conclusion These data suggest that all MBC patients
regardless of age of diagnosis, history of multiple primary
cancers, or family history of MBC should be offered MGPT.
Keywords Male breast cancer  Multi-gene panel testing 
BRCA2  CHEK2  PALB2
Introduction
While the incidence of male breast cancer (MBC) in the
general population is low (1:1000), it can be significantly
elevated for patients with an underlying genetic predisposi-
tion. Comprehensive genetics evaluation of all MBC patients
is important, as identification of various cancer-predisposing
mutations can drastically impact medical management for
patients and their family members. The BRCA1 and BRCA2
genes, implicated in hereditary breast and ovarian cancer
syndrome (HBOC), have been associatedwith increased risks
for MBC, and it is currently recommended that individuals
with a personal or family history of male breast cancer
undergo testing of these genes [1]. BRCA2 is the most fre-
quently mutated gene in MBC cohorts, having been reported
in 4–40% of MBC patients, depending on the population
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studied and the presence/absence of additional clinical history
supporting a diagnosis of HBOC [2–9]. Cumulative lifetime
breast cancer risks for male BRCA1 and BRCA2 pathogenic
variant carriers are 1–2 and 5–10%, respectively. In addition
to breast cancer, males with BRCA1 or BRCA2 pathogenic
variants face increased lifetime risks for prostate and pan-
creatic cancers [10–12].
Beyond BRCA1/BRCA2, data are limited regarding
genetic predisposition to MBC. Two independent studies
have linked CHEK2 1100delC with MBC [13, 14]; how-
ever, results from multiple other studies have not confirmed
this association [15–22]. Furthermore, the role of other
CHEK2 pathogenic variants in MBC is yet to be explored.
Germline pathogenic variants in the PTEN, androgen
receptor (AR), NF1, and PALB2 genes have also been
reported in MBC patients; however, associations with
MBC have not been well-studied and risk estimates are not
currently available [23–26].
The clinical availability of multi-gene panel testing
(MGPT) presents an opportunity for patients to undergo
comprehensive analysis of a wide range of cancer sus-
ceptibility genes, including those with and without estab-
lished links to MBC. Despite increased utilization of such
testing in hereditary cancer diagnostics, data remain lim-
ited regarding the yield of such testing for MBC patients.
In a recent study of breast cancer patients who underwent
MGPT, 31.8% (n = 7/22) of MBC cases tested positive for
pathogenic or likely pathogenic variants: BRCA1 (1),
BRCA2 (3), PALB2 (1), CHEK2 (1), and ATM (1) [8].
These results are yet to be validated in larger MBC cohorts.
To better understand the genetic contribution to MBC and
the yield of MGPT in this population, we retrospectively
assessed a cohort of MBC patients referred for MGPT.
Methods
Study population
Clinical histories and molecular results were retrospectively
reviewed for all MBC patients (n = 715) who underwent
MGPT at Ambry Genetics between March 2012 and June
2016 (Aliso Viejo, CA). The following demographic and
clinical history information was obtained from test requisi-
tion forms and clinic notes submitted by ordering providers:
age at testing, ethnicity, BRCA1/2 testing history, and per-
sonal/family cancer history. Patients were excluded if they
were known BRCA1/2 pathogenic variant carriers prior to
MGPT (n = 1), if heterozygosity ratios of less than\25%
were observed for any reported alterations detected in the
patient (n = 3), or if the only information suggesting a
MBC diagnosis was an ICD-9 code (n = 3), leaving 708
MBC patients eligible for further study.
Laboratory methods
Patients underwent comprehensive analysis of cancer sus-
ceptibility genes using a variety of gene panels (Online
Resource 1). Genomic deoxyribonucleic acid (gDNA) was
isolated from the patient’s blood or saliva specimen using a
standardized methodology (Qiagen, Valencia, CA) and
quantified by spectrophotometer (Nanodrop; Thermoscien-
tific, Pittsburgh, PA, or Infinite F200; Tecan, San Jose, CA).
Sequence enrichment was performed by incorporating the
gDNA onto a microfluidics chip or into microdroplets along
with primer pairs or by a bait-capture methodology using
long biotinylated oligonucleotide probes (Fluidigm, South
San Francisco, CA, RainDance Technologies, Billerica, MA
or Integrated DNA Technologies, San Diego, CA), followed
by PCR and NGS analysis (Illumina, San Diego, CA) of all
coding regions ± five bases into introns and untranslated
regions (50UTR and 30UTR). Sanger sequencing was per-
formed for any regions with insufficient depth of coverage
for reliable heterozygous variant detection and for verifica-
tion of variant calls, other than known non-pathogenic
alterations. A targeted chromosomal microarray was used
for the detection of gross deletions and duplications for each
sample (Aglient, Santa Clara, CA). Initial data processing
and base calling were performed with RTA 1.12.4 (HiSeq
Control Software 1.4.5; Illumina). Sequence quality filtering
was executed with CASAVA software (version 1.8.2; Illu-
mina, Hayward, CA). Sequence fragments were aligned to
the reference human genome (GRCh37), and variant calls
were generated using CASAVA. A minimum quality
threshold of Q20 was applied, translating to an accuracy of
[99.9% for the called bases.
Variant classification
Variants were annotated with the Ambry Variant Analyzer,
a proprietary alignment and variant annotation software
(Ambry Genetics) that assigned variants according to a
five-tier variant classification protocol [pathogenic muta-
tion; variant, likely pathogenic (VLP); variant of unknown
significance (VUS); variant, likely benign (VLB); and
benign], based on published recommendations from the
American College of Medical Genetics and Genomics and
the International Agency for Research on Cancer [27–29].
Statistical analysis
The frequency of pathogenic or likely pathogenic variants
was calculated for ATM, BARD1, BRCA1, BRCA2, BRIP1,
CDH1, CHEK2, MRE11A, NBN, NF1, PALB2, PTEN,
RAD50, RAD51C, RAD51D, and TP53. To avoid potential
bias introduced by prior BRCA1/2 testing and the varying
number of genes tested by panel type, the diagnostic yield of
576 Breast Cancer Res Treat (2017) 161:575–586
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MGPT was assessed using MBC patients tested for all 16
breast cancer genes (n = 512) and then stratified by prior
BRCA1/2 testing status. Clinical history comparisons were
performed using patients tested for all 16 breast cancer
genes, after removal of cases with pathogenic variants in
genes not associated with breast cancer (n = 6), multiple
pathogenic variants in breast cancer genes (n = 5), patients
with monoallelic MUTYH pathogenic variants as the only
pathogenic variant detected (n = 5), and patients carrying
the low-risk CHEK2 p.I157T variant (n = 6). Multivariable
logistic regression (controlling for age, ethnicity and panel
ordered) was performed to compare personal history of
additional primary cancers and family history of MBC. A
two-sample t test was used to test the age difference between
groups.
Breast cancer risk estimation
Among 708 MBC patients, 538 were Caucasian or Ashke-
nazi Jewish. Of these, individuals tested for all 16 breast
cancer predisposition genes (n = 421) were subjected to
breast cancer risk estimation. The non-Finn European pop-
ulation (NFE) in the Exome Aggregation Consortium
(ExAC) dataset [30], excluding The Cancer Genome Atlas
(TCGA) exomes, were used as public controls for case–
control association studies with Caucasian breast cancer
cases, consistent with the effective use of this dataset for
estimation of ovarian and prostate cancer risk in recent
studies [31, 32]. ExAC filter PASS/non-PASS rather than
PASS only variants from the ExAC NFE-non TCGA dataset
were used because multiple pathogenic variants validated by
Ambry Genetics were excluded from the filter PASS cate-
gory of ExAC. Restricting to PASS only variants led to
reduced numbers of variants in controls and inflated breast
cancer risks associated with each gene. To account for low-
quality ExAC variants, recurrent variants observed at sig-
nificantly different frequencies in other populations or with
sequencemisalignment were excluded. All remaining loss of
function variants (nonsense, frameshift, consensus dinu-
cleotide splice site (±1 or 2), and any missense variants
defined as pathogenic in ClinVar by clinical laboratories) in
breast cancer cases and ExAC controls were selected for
inclusion. A series of filtering steps were applied (Supple-
mentary Methods) to normalize differences in the breast
cancer cases and the ExAC controls. Breast cancer cases
carrying two or more pathogenic variants were excluded
because of potential for inflation of breast cancer risks.While
this filter was not applied to ExAC data due to the absence of
individual-level genotype data, these events are rare in the
general population and should only have a minor, conser-
vative impact on risks estimates. Similarly, large genomic
rearrangements of one or more exons were excluded from
cases and ExAC controls because rearrangements were not
validated among controls. Sensitivity analyses were also
conducted when restricting to cases without prior BRCA1/2
testing, to account for ascertainment bias (n = 268). Asso-




This cohort was primarily Caucasian (66.1%), with other
ethnicities each representing B10% of patients tested
(Table 1). Ethnicity was unspecified for 6.2% of the cohort.
The majority of patients were age 60 and older at the time of
testing (71.7%) and at the time of first breast cancer diagnosis
(61.0%). Four percent ofMBCpatients had a second primary
breast cancer, and additional non-breast primary cancers
were reported for 23.4%. The most common additional
cancer was prostate cancer, which was significantly enriched
in this cohort with a frequency of 9.5% (n = 67) compared
with the general population (0.13%; p = 10-16) [33]. A
family history of MBC was reported for 6.4% of patients.
Test results
Ninety-seven of 708MBCpatients were found to have at least
one pathogenic or likely pathogenic variant in a breast cancer
susceptibility gene (Table 2). Seven of these patients were
found to carry two pathogenic variants including one biallelic
ATM carrier with a clinical diagnosis of ataxia-telangiectasia,
two ATM/BRCA2 carriers, one BRIP1/BRCA2 carrier, one
BRCA1/CHEK2 carrier, one BARD1/PALB2 carrier, and one
CHEK2/PALB2 carrier. BRCA2 and CHEK2 were the most
frequently alteredgenes,with pathogenic variants identified in
11.0 and 4.1% of MBC patients with no prior BRCA1/2 test-
ing, respectively (Table 3). No pathogenic variants were
identified in the following hereditary breast cancer genes:
CDH1, PTEN, RAD50, RAD51C, and TP53.
Diagnostic yield
To assess the diagnostic yield of MGPT for MBC patients,
results were analyzed for patients tested for all 16 breast
cancer genes (n = 512) (Table 4). The overall mutation-
positive rate for breast cancer susceptibility genes for
patients with no prior BRCA1/2 testing reported was 18.1%
(N = 64/354), with 1.1% (n = 4) of patients carrying
pathogenic variants in two different breast cancer genes. The
overallmutation-positive rate for breast cancer susceptibility
genes for patients with prior BRCA1/2 testing reported was
7.6% (N = 12/158), with 1 patient carryingmutations in two
different breast cancer genes. Of note, two patients in this
Breast Cancer Res Treat (2017) 161:575–586 577
123
group tested positive forBRCA2 gross deletions thatwere not
previously detected because gross deletion/duplication
analysis had not been previously performed.
Clinical history comparisons
The average age of diagnosis was similar for men with
(63.5 ± 2.7 years) and without (62.3 ± 1.2 years;
p = 0.43) pathogenic variants (Fig. 1). In addition, there
was no significant difference in history of multiple primary
cancers between patients with and without pathogenic
variants (p = 0.13) (Fig. 2). However, patients with
pathogenic variants were more likely to report multiple
primary breast cancers (p = 4.16 9 10-3), with BRCA2
accounting for all cases. There was no significant differ-
ence in family history of MBC (p = 0.37).
The average age of diagnosis for men with any CHEK2
pathogenic variants (58.8 ± 6.4 years) was not signifi-
cantly different from men with non-CHEK2 pathogenic
variants (64.6 ± 3.0 years; p = 0.09) or from men who did
not test positive (62.3 ± 1.2 years; p = 0.26); however,
CHEK2 1100delC carriers had a significantly lower aver-
age age of diagnosis (53.8 ± 9.6 years) compared to men
with non-CHEK2 variants (p = 0.03). No significant dif-
ferences were observed between average age at breast
cancer diagnosis for CHEK2 1100delC carriers compared
to other CHEK2 pathogenic variants (63.7 ± 9.6 years;
p = 0.09) or to men who did not test positive (p = 0.07),
though these trended toward significance.
Gene-specific risks of MBC
Case–control analyses were performed based on sequencing
results from 421 Caucasian MBC patients and 26,911 ExAC
NFE-nonTCGAcontrols. Pathogenic variants inBRCA2 and
CHEK2 were significantly associated with increased risk of
MBC (BRCA2 OR = 13.9, p = 1.92 9 10-16; CHEK2
OR = 2.43, p = 1.82 9 10-3) (Table 5). Additional stud-
ies evaluating risks associated with CHEK2 1100delC and
excluding common/low-risk missense variants (p.Ile157Thr
and p.Ser428Phe) showed that truncating variants inCHEK2
are associated with moderately increased risks of MBC
(OR = 3.8; 95% CI 2.1–6.8; p = 1.51 9 10-4) (Table 5).
Variants in PALB2 were also significantly associated with a
high risk of MBC (OR = 6.6, p = 0.013) (Table 5). How-
ever, this risk estimate is uncertain due to small numbers of
MBCs with pathogenic variants (95% CI 1.70–21.09).
Interestingly, few pathogenic variants were identified in
ATM and BRCA1, which are commonly mutated in female
familial breast cancer. No significant associations withMBC
Table 1 Demographics of overall male breast cancer cohort
(n = 708)
Demographic N Total %
Ethnicity
Caucasian 468 708 66.1
Ashkenazi Jewish 70 708 9.9
African American 58 708 8.2
Asian 23 708 3.2
Hispanic 16 708 2.3
Middle Eastern 5 708 0.7
Native American 1 708 0.1
Mixed ethnicity 20 708 2.8
Other 3 708 0.4
Unknown 44 708 6.2
Panel ordered (total number of genes on panel)
BRCAplus (5–6) 115 708 16.2
GYNplus (9–13) 7 708 1.0
BRCAplus-expanded 17 708 2.4
BreastNext (14–18) 297 708 41.9
OvaNext (19–24) 66 708 9.3
PancNext (range) 5 708 0.7
CancerNext (22–32) 148 708 20.9
CancerNext-expanded (43–49) 53 708 7.5
Age at testing
20–29 2 708 0.3
30–39 18 708 2.5
40–49 43 708 6.1
50–59 138 708 19.5
60–69 234 708 33.1
70–79 189 708 26.7
80–89 75 708 10.6
90 and older 9 708 1.3
Age at diagnosisa
20–29 10 687 1.5
30–39 28 687 4.1
40–49 70 687 10.2
50–59 160 687 23.3
60–69 210 687 30.6
70–79 158 687 23.0
80–89 47 687 6.8
90 and older 4 687 0.6
Testing history
Prior BRCA1/2 testing 223 708 31.5
Clinical Historya
Family history male breast cancer 41 643 6.4
Multiple primary breast cancers 28 706 4.0
Additional non-breast primary cancers 166 708 23.4
a Age at diagnosis and clinical history were not provided for all men
in the cohort
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risks were observed. Sensitivity analyses excluding MBCs
with prior testing ofBRCA1/2 showed very similar effects for
pathogenic variants in these genes (Online Resource 3).
Discussion
Previously reported cohorts of MBC patients undergoing
MGPT have included 22–51 cases [8, 9], making this the
largest reported collection to date of MBC patients
undergoing MGPT. As expected, BRCA2 accounted for the
largest percentage of pathogenic variants, whereas the
observed frequency of CHEK2 pathogenic variants (4.1%)
was greater than expected based on previous reports of
MBC in CHEK2 cohorts. These findings support recent
reports of the CHEK2 pathogenic variant frequencies
among MBC cases in the MGPT setting (4.5–7.8%) [8, 9].
While BRCA2 is an established MBC susceptibility gene,
literature regarding an association of CHEK2 with MBC is
conflicting. Despite an initial report in 2002 concluding
that CHEK2 1100delC is associated with a tenfold risk for
MBC [13], and a subsequent report of an association
between 1100delC and MBC in the Dutch population [14],
multiple other studies have not affirmed this association
Table 3 Frequency of pathogenic variants in breast cancer genes in overall MBC cohort (n = 708)














BRCA2 53 480 11.0 2 197 1.0 55 677 8.1




11 386 2.8 5 195 2.6 16 581 2.8
CHEK2
(I157T only)
5 386 1.3 1 195 0.5 6 581 1.0
ATMb 6 390 1.5 0 196 0.0 6 586 1.0
BRCA1 6 480 1.3 0 197 0.0 6 677 0.9
NF1 2 354 0.6 1 158 0.6 3 512 0.6
PALB2 2 417 0.5 3 204 1.5 5 621 0.8
RAD51D 1 354 0.3 0 158 0.0 1 512 0.2
BRIP1 1 370 0.3 0 194 0.0 1 564 0.2
MRE11A 1 370 0.3 0 194 0.0 1 564 0.2
NBN 1 370 0.3 0 194 0.0 1 564 0.2
BARD1 0 370 0.0 2 194 1.0 2 564 0.4
a The total number of men tested varies by gene, as not all men were tested by the same panel of genes
b ATM biallelic individual was counted only once
Table 4 Findings among MBC patients tested for 16 breast cancer genes (n = 512)
Result category No prior BRCA testing (n = 354) Prior BRCA testing (n = 158)
N % N %
Pathogenic/likely pathogenic variant 64 18.1 12 7.6
Pathogenic/likely pathogenic variant(s) in a single gene 60a 16.9 11 7.0
BRCA1/2 39 11.0 2 1.3
Non-BRCA1/2 21 5.9 9 5.7
Pathogenic/likely pathogenic variant(s) in multiple genes 4 1.1 1 0.6
Combination of BRCA1/2 and non-BRCA1/2 genes 3 0.8 0 0.0
Multiple non-BRCA1/2 genes 1 0.3 1 0.6
Pathogenic/likely pathogenic variant ? VUS 16 4.5 5 3.2
VUS only 59 16.7 34 21.5
Negative 231 65.3 112 70.9
a 59 had a single pathogenic/likely pathogenic variant and 1 had biallelic ATM mutations
582 Breast Cancer Res Treat (2017) 161:575–586
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[15–22]. The limited number of probands affected with
MBC (i.e., under 100 in most studies) and the lack of full
sequencing of CHEK2 in published cohorts may explain
these conflicting reports. In the current study, CHEK2
protein-truncating variants were associated with a 3.8-fold
increased risk for MBC, which is highly consistent with
findings from the studies of breast cancer families. Confi-
dence intervals ranged from 2.1 to 6.8 suggesting that
CHEK2 is a moderate risk gene for MBC. In contrast,
BRCA2 pathogenic variants were associated with much
higher risks of MBC (OR = 13.9; 95% CI 8.5–22.5).
Multiple ATM and PALB2 pathogenic variants were also
detected among MBC patients in this cohort. To our
knowledge, this is only the second report of MBC in ATM
heterozygotes [8] and the first report of MBC in a patient
with ataxia-telangiectasia. Of note, two of the five ATM
pathogenic variant carriers in the refined 16-gene subgroup
were multiple pathogenic variant carriers, including one
ATM biallelic carrier and one ATM/BRCA2 carrier. In the
larger cohort, there was also one additional ATM/BRCA2
carrier. Furthermore, ATM pathogenic variants were not
significantly associated with MBC (Table 5). These
observations suggest ATM may act as an MBC risk mod-



























isFig. 1 Average age at breast























Fig. 2 Clinical histories of pathogenic carriers versus non-carriers
Table 5 Breast cancer risks associated with pathogenic variants pooled by gene among Caucasian male breast cancer cases
Gene Ambry cases ExAC controls Cancer risk
Mutated alleles Cases Mutated alleles Cases OR 95% CI lower 95% CI upper p value
ATM 2 421 90 26,644 1.4 0.3 5.1 0.66
BRCA1 2 394 74 26,911 1.8 0.3 6.8 0.30
BRCA2 21 394 105 26,791 13.9 8.5 22.5 1.92 9 10-16
CHEK2 All 17 421 424 25,215 2.4 1.4 3.9 1.82 9 10-3
CHEK2_c.1100delC 8 421 127 25,215 3.8 1.7 7.8 1.82 9 10-3
CHEK2 W/O I157T/S428F 10 421 163 25,215 3.7 1.9 7.0 6.24 9 10-4
CHEK2 W/O I157T 12 421 191 25,215 3.8 2.1 6.8 1.51 9 10-4
CHEK2 I157T 5 421 233 25,215 1.3 0.5 3.0 0.60
PALB2 3 421 29 26,869 6.6 1.7 21.1 0.013
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123
pathogenic variants among MBC families, with a fre-
quency ranging from 0.8 to 6.4%, although most reports
have not met statistical significance [23, 34–37]. One study
reported that PALB2 pathogenic variant carriers were four
times more likely than PALB2-negative patients to have a
relative with MBC (p\ 0.001) [34]. In addition, Antoniou
et al. reported an eightfold increased risk for MBC in
PALB2 carriers from moderate- and high-risk families;
however, this did not reach statistical significance
(p = 0.08) [35]. Consistent with both reports, PALB2
pathogenic variants in the current study were associated
with a 6.6-fold increased risk of MBC (Table 5). Further
association studies, in families and in the general popula-
tion, are needed to confirm the association of genes such as
ATM and PALB2 with MBC and to calculate more precise
breast cancer risks for males with pathogenic variants in
these genes.
Five (1.41%) of the MBC patients in the refined sub-
group with no prior BRCA testing carried multiple patho-
genic variants. As mentioned above, one of the MBC
patients had biallelic ATM pathogenic variants and was
noted to have a clinical history of ataxia-telangiectasia on
the requisition form. Three of the multiple pathogenic
variant carriers had a combination of pathogenic variants in
one high-risk gene and one moderate risk gene: BRCA1/
CHEK2, BRCA2/ATM, and BRCA2/BRIP1. The other
multiple pathogenic variant carriers had mutations in two
moderate-risk genes: CHEK2/PALB2. Excluding skin
cancer, only the BRCA2/ATM pathogenic variant carrier
reported multiple primary cancers (MBC and prostate
cancer). The percentage of multiple pathogenic variants in
this cohort and other reported MBC cohorts appears to be
similar to multiple pathogenic variants in female breast
cancer cohorts [8, 9].
Due to the relatively low number of pathogenic variants
in other non-breast cancer genes in this cohort, it is difficult
to assess whether MBC is an unrecognized component of
the cancer spectra for these genes. Interestingly, several
men tested positive for a pathogenic variant in genes
associated with a syndromic presentation, including APC
and SDHA. These patients did not have classical presen-
tation of the associated syndromic features, indicating that
gene-specific testing likely would not have been considered
(Online Resource 2). Breast cancer—male or female—is
not currently considered a component of the cancer spectra
for these genes. While identification of a pathogenic vari-
ant in these cases is likely to impact medical management
for other cancers, the result offers little insight into the
most appropriate management of MBC risk, specifically, or
whether other males in the family should be considered for
testing and/or high-risk breast cancer screening.
No PTEN pathogenic variants were detected among
MBC probands, despite previous reports of PTEN carriers
with MBC. Since PTEN pathogenic variants are typically
associated with Cowden syndrome (i.e., the presence of
macrocephaly and characteristic mucocutaneous features in
addition to cancer predisposition), it is likely that MBC
patients with clinical histories suggestive of Cowden syn-
drome would be referred for PTEN testing alone rather than
MGPT. Therefore, the absence of PTEN mutations in this
cohort does not necessarily contradict previous reports.
Similarly, pathogenic variants were not identified in TP53
or CDH1 in this cohort. While male breast cancer is not a
major feature associated with either of these genes, it is
possible that men with clinical histories suggestive of Li–
Fraumeni syndrome or Hereditary Diffuse Gastric Cancer
syndrome would have had single gene testing instead of
MGPT, potentially introducing ascertainment bias with
respect to these genes.
With the exception of men with CHEK2 1100delC, age
of diagnosis was not predictive of positive test results.
Although the number of men carrying the CHEK2
1100delC in this cohort is small, the significantly younger
age of diagnosis in this subset may indicate that men with
this specific pathogenic variant may warrant surveillance
and/or a higher index of suspicion for male breast cancer at
a younger age compared to men with other pathogenic
variants. Family history of MBC and additional primary
cancer diagnoses were also not predictive of positive
results in this cohort, consistent with current NCCN
BRCA1/2 testing guidelines which recommend testing for
MBC patients regardless of age at diagnosis or other
clinical history. In contrast, multiple breast primary cancers
were only identified in BRCA2 pathogenic variant carriers
in this cohort, suggesting a role for first-line BRCA1/
BRCA2 testing in men with this presentation.
The identification of pathogenic variants in MBC
patients may have clinical implications both for the
affected men and their relatives. For example, breast cancer
screening is recommended for BRCA1/BRCA2-positive
men, beginning at age 35, and increased colon surveillance
is recommended for CHEK2-positive individuals [1].
Several of the pathogenic variants identified in this cohort
are associated with risks for other cancers, and their
identification allows for increased surveillance which may
lead to earlier detection of subsequent cancers. Many of the
pathogenic variants identified in this cohort also carry
significant risks for breast and ovarian cancer in women.
Therefore, identification of variants in MBC patients
allows for testing at-risk family members and increased
surveillance and/or risk-reducing surgeries for positive
relatives. Given the clinical implications for patients and
their families, there appears to be utility in choosing a
MGPT approach for MBC patients.
There are several limitations to this study. While pre-
vious BRCA1/2 testing was controlled for in this analysis, it
584 Breast Cancer Res Treat (2017) 161:575–586
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is possible that previousBRCA1/2 testing was underreported
in this group. Clinical historywas ascertained by information
reported on test requisition forms, and were verified by
pedigree review when provided. As such, the analysis of
secondary cancers and family history of cancer may be
limited by the accuracy and completeness of the data pro-
vided. However, results from a recent study demonstrated
that clinical history on test requisition forms at Ambry
Genetics is highly accurate and complete for probands and
highly accurate for relatives, with completeness correlating
with relationship to the proband (i.e.,more complete for first-
and second-degree relatives and less complete for third-de-
gree relatives and beyond) [38]. In addition, as this is a ret-
rospective review of men selected for different clinical
genetic tests and may over-represent male breast cancer
cases in the setting of a family history also indicative of a
hereditary predisposition for cancer, the results of the study
may be influenced by ascertainment bias or be specifically
applicable to a high-risk population. Finally, segregation
data in families withmultiple cases ofmale breast cancer and
in families with multiple pathogenic variants from this
cohort are not available. Segregation data could potentially
clarify the association between male breast cancer and the
identified pathogenic variants in these families.
Results from this study build upon the current under-
standing of hereditary susceptibility to MBC. These data
lend support to a MGPT approach for MBC patients
regardless of age at diagnosis, history of multiple primary
cancers, and family history of MBC. Furthermore, these
data support CHEK2 as a MBC susceptibility gene. The
observed pathogenic variant frequency in this MBC cohort
highlights the immediate need for studies investigating the
most appropriate screening and risk management tools for
MBC patients, particularly in cases with pathogenic vari-
ants in genes beyond BRCA1/2.
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